Dr Hartmut Kristeleit
- London, United Kingdom
- En, Fr, De, En, Fr, De
- Best at: Breast Cancer, Acute Oncology
Dr Hartmut Kristeleit is a Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust and lead for Acute Oncology at South London Healthcare NHS Trust. He specializes in the treatment of early and advanced breast cancer and acute oncology. Dr Kristeleit completed his undergraduate studies at the Universities of Bonn (Germany), Lausanne (Switzerland) and Barts and The London School of Medicine. He has a first class medical degree from Bonn University and performed his post graduate and specialist training in London teaching hospitals. He spent four years as an AVON Clinical Research Fellow at the Breakthrough Breast Cancer Research Centre investigating novel targets in familial breast cancer. He was appointed as a Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust in 2009. He provides the medical oncology service for breast cancer at Queen Elizabeth and Queen Mary's hospitals and is currently the lead clinician for Acute Oncology in the South East London Accountable Cancer Network. Dr Kristeleit has a keen research interest in the role of novel therapies for breast cancer. He is an investigator on numerous clinical trials for breast cancer and chairs the oncology research committee at Guy's and St Thomas'. He gives regular lectures for the University of London and has been invited to speak at national conferences and international meetings.
Achievements of Dr Hartmut Kristeleit
Information about Dr Hartmut Kristeleit
- chemotherapy - 4
breast cancer articles - Impact Factor
- breast neoplasms - 2
- oncology therapy - 2
The addition of adjuvant trastuzumab therapy for 1 year to standard chemotherapy significantly improved disease-free survival and overall survival versus chemotherapy alone in a number of pivotal early breast cancer studies. Here we review long-term follow-up data on the efficacy, cardiac safety, and general safety of trastuzumab in these pivotal studies. We also evaluate ongoing phase II/III adjuvant trials with newer HER2-targeted agents and the efficacy and safety of the recently developed subcutaneous (SC) formulation of trastuzumab in early breast cancer. Long-term follow-up data confirm the significant survival benefit afforded by the addition of trastuzumab to chemotherapy in patients with HER2-positive disease, with an acceptable safety profile. Long-term cardiac safety data suggest that the incidence of cardiac adverse events is maintained at a relatively low level with continued follow-up. At this present time, 1 year of trastuzumab treatment remains the standard of care in HER2-positive early breast cancer. Future adjuvant trastuzumab treatment strategies should focus on reducing cardiotoxicity, particularly in elderly patients, by identifying potential predictive biomarkers of cardiac dysfunction. Clinicians must also decide whether to omit trastuzumab in women who would achieve little benefit from treatment to avoid cardiotoxicity.
Map of connections